<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A3089</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 3089 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  DONALD A. GUARDIAN</p>

<p class=bpuSponsor>District 2 (Atlantic)</p>

<p class=bpuSponsor>Assemblywoman  LUANNE M. PETERPAUL</p>

<p class=bpuSponsor>District 11 (Monmouth)</p>

<p class=bpuSponsor>Assemblywoman  ANNETTE QUIJANO</p>

<p class=bpuSponsor>District 20 (Union)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Assemblywomen Ramirez, Drulis, Reynolds-Jackson, Hall and
Bagolie</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Authorizes pharmacists to dispense HIV prophylaxis
without individual prescription under certain circumstances; mandates
prescription benefits coverage. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning pharmacists and supplementing Titles
17, 26, 45, and 52 of the Revised Statutes and Title 17B of the New Jersey
Statutes.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    As used in this act:</p>

<p class=MsoNormal style='line-height:150%'>     CDC PEP guidelines means the
Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual,
Injection Drug Use, or Other Nonoccupational Exposure to HIV  United States,
2016, or any subsequent guidelines, published by the federal Centers for
Disease Control and Prevention.</p>

<p class=MsoNormal style='line-height:150%'>     CDC PReP guidelines means
the 2017 Preexposure Prophylaxis for the Prevention of HIV Infection in the
United States  2017 Update: A Clinical Practice Guideline, or any subsequent
guidelines, published by the federal Centers for Disease Control and
Prevention.</p>

<p class=MsoNormal style='line-height:150%'>     HIV means the human
immunodeficiency virus.</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means a fixed-dose combination of tenofovir disoproxil fumarate (TDF) (300 mg)
with emtricitabine (FTC) (200 mg), or another drug or drug combination
determined by the State Board of Pharmacy to meet the same clinical eligibility
recommendations provided in the CEC PReP guidelines.</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means:  tenofovir disoproxil fumarate (TDF) (300 mg) with emtricitabine (FTC)
(200 mg), taken once daily, in combination with either raltegravir (400mg),
taken twice daily, or dolutegravir (50mg), taken once daily; tenofovir disoproxil
fumarate (TDF) (300 mg) with emtricitabine (FTC) (200 mg), taken once daily, in
combination with darunavir (800mg) and ritonavir (100mg), taken once daily; or
another drug or drug combination determined by the State Board of Pharmacy to
meet the same clinical eligibility recommendations provided in the CEC PRP
guidelines.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    a.  Notwithstanding any
other provision of law to the contrary, a pharmacist may initiate and furnish
HIV preexposure prophylaxis or HIV postexposure prophylaxis to a patient
without an individual prescription pursuant to a standing order issued to the
pharmacist by the Commissioner of Health or, if the commissioner is not a duly
licensed physician, the Deputy Commissioner for Public Health Services.  A
standing order shall be issued to a pharmacist upon request, provided that the
pharmacist satisfies the training requirements set forth in subsection b. of
this section and certifies that the pharmacist will adhere to the requirements
set forth in subsection c. of this section concerning the protocols for
initiating and furnishing HIV preexposure prophylaxis and the requirements set
forth in subsection d. of this section concerning the protocols for initiating
and furnishing HIV postexposure prophylaxis to patients without an individual
prescription.  In no case shall a patient be authorized to waive the
consultation required pursuant to subsection c. or subsection d. of this
section.</p>

<p class=MsoNormal style='line-height:150%'>     b.    A pharmacist shall not
be authorized to furnish HIV preexposure prophylaxis or HIV postexposure
prophylaxis to a patient without an individual prescription unless the
pharmacist completes a training program, approved by the State Board of
Pharmacy in consultation with the Department of Health, concerning the use of
HIV preexposure prophylaxis and HIV postexposure prophylaxis.  At a minimum,
the training program shall include information about financial assistance
programs available to patients to assist with the costs of HIV preexposure
prophylaxis and HIV postexposure prophylaxis.  </p>

<p class=MsoNormal style='line-height:150%'>     c.     A pharmacist shall
furnish at least a 30-day supply, and up to a 60-day supply, of HIV preexposure
prophylaxis to a patient without an individual prescription if the following
requirements are met:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   The patient is
HIV-negative, as documented by a negative HIV test result obtained within the
previous seven days from an HIV antigen/antibody test or antibody-only test or
from a rapid, point-of-care fingerstick blood test approved by the federal Food
and Drug Administration.  If the patient does not provide evidence of a
negative HIV test in accordance with this paragraph, the pharmacist shall order
an HIV test.  If the test results are not ordered directly to a pharmacist, the
pharmacist shall verify the test results to the pharmacists satisfaction.  If
the patient tests positive for HIV infection, the pharmacist or person
administering the test shall direct the patient to a primary care provider,
provide the patient with information and resources concerning treatment
providers and HIV treatment clinics in the region, and take all other actions
required under State and federal law in response to a positive test for HIV;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   The patient does not
report any signs or symptoms of acute HIV infection on a self-reported
checklist of acute HIV infection signs and symptoms;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   The patient does not
report taking any contraindicated medications, and the pharmacist reviews the
patients prescription monitoring information to confirm no contraindicated
prescriptions have been issued or dispensed to the patient in the past six
months;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   The patient has not been
furnished with HIV preexposure prophylaxis without an individual prescription
within the past two years;</p>

<p class=MsoNormal style='line-height:150%'>     (5)   The pharmacist provides
counseling to the patient on the ongoing use of HIV preexposure prophylaxis,
which may include education about side effects, safety during pregnancy and
breastfeeding, adherence to recommended dosing, and the importance of timely
testing and treatment, as applicable, for HIV, renal function, hepatitis B,
hepatitis C, sexually transmitted diseases, and pregnancy for individuals of
child-bearing capacity.  The pharmacist shall notify the patient that the
patient will not be eligible to continue receiving HIV preexposure prophylaxis
unless the patient is seen by a primary care provider and issued a prescription
for the HIV preexposure prophylaxis, and that the patient may be furnished with
no more than a 60-day supply of HIV preexposure prophylaxis by a pharmacist
without an individual prescription within any given two year period;</p>

<p class=MsoNormal style='line-height:150%'>     (6)   The pharmacist
documents, to the extent possible, the services provided by the pharmacist in
the patients record in the record system maintained by the pharmacy, and
includes the dispensation of the HIV preexposure prophylaxis in the
prescription monitoring database established pursuant to P.L.2007, c.244
(C.45:1-45 et al.) with a note indicating the HIV preexposure prophylaxis was
provided without an individual prescription pursuant to this section; and</p>

<p class=MsoNormal style='line-height:150%'>     (7)   The pharmacist notifies
the patients primary care provider that the pharmacist furnished the patient
with HIV preexposure prophylaxis pursuant to this section.  If the patient does
not have a primary care provider, or refuses to consent to the pharmacist
providing notice to the primary care provider pursuant to this paragraph, the
pharmacist shall provide the patient with a list of physicians and surgeons,
clinics, or other health care service providers to contact regarding ongoing
care for HIV preexposure prophylaxis.  The Department of Health shall publish
and maintain a current list of providers for pharmacists to use for the
purposes of this paragraph, which list may be made available on the
departments Internet website.</p>

<p class=MsoNormal style='line-height:150%'>     d.    A pharmacist shall
furnish a complete course of HIV postexposure prophylaxis to a patient without
an individual prescription if the following requirements are met:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   The pharmacist confirms
with the patient that the exposure to HIV occurred within the previous 72 hours
and the patient otherwise meets the clinical criteria for HIV postexposure
prophylaxis consistent with the CDC PEP guidelines;<span style='font-size:11.0pt;
line-height:150%;font-family:"Calibri",sans-serif;color:#1F497D'> </span></p>

<p class=MsoNormal style='line-height:150%'>     (2)   The pharmacist provides
HIV testing that is classified as waived under the federal Clinical Laboratory
Improvement Amendments of 1988, 42 U.S.C. s.263a, or determines the patient is
willing to undergo HIV testing consistent with the CDC PEP guidelines;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   The pharmacist provides
counseling to the patient on the use of HIV postexposure prophylaxis consistent
with the CDC PEP guidelines, which may include education about side effects, safety
during pregnancy and breastfeeding, adherence to recommended dosing, and the
importance of timely testing and treatment, as applicable, for HIV and sexually
transmitted diseases.  The pharmacist shall additionally inform the patient of
the availability of HIV preexposure prophylaxis for persons who are at
substantial risk of acquiring HIV; and</p>

<p class=MsoNormal style='line-height:150%'>     (4)   The pharmacist notifies
the patients primary care provider that the pharmacist provided the patient
with a complete course of HIV postexposure prophylaxis.  If the patient does
not have a primary care provider, or refuses to consent to the pharmacist
providing notice to the primary care provider pursuant to this paragraph, the
pharmacist shall provide the patient with a list of physicians and surgeons, clinics,
or other health care service providers to contact regarding followup care for
HIV postexposure prophylaxis.  The Department of Health shall publish and
maintain a current list of providers for pharmacists to use for the purposes of
this paragraph, which list may be made available on the departments Internet
website.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, no group or
individual hospital service corporation contract providing hospital or medical
expense benefits shall be delivered, issued, executed, or renewed in this State
or approved for issuance or renewal in this State by the Commissioner of
Banking and Insurance, on or after the effective date of this act, unless the
contract provides benefits to any subscriber or other person covered thereunder
for </span>HIV preexposure prophylaxis and HIV postexposure prophylaxis
furnished without an individual prescription pursuant to the requirements of
section 2 of P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the contract to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>A contract
offered by a group or individual hospital service corporation</span> shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require a contract offered by a group or individual
hospital service corporation to provide coverage for HIV preexposure
prophylaxis or HIV postexposure prophylaxis furnished by a pharmacist at an
out-of-network pharmacy, unless the contract has an out-of-network pharmacy
benefit.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     d.    The
provisions of this section shall apply to all contracts in which the hospital
service corporation has reserved the right to change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV postexposure
prophylaxis be shown to have been ineffective as a condition of providing
prescription benefits coverage for the prophylaxis.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, n</span>o group
or individual medical service corporation contract providing hospital or
medical expense benefits shall be delivered, issued, executed, or renewed in
this State or approved for issuance or renewal in this State by the
Commissioner of Banking and Insurance, on or after the effective date of this
act, unless the contract provides benefits to any subscriber or other person
covered thereunder for HIV preexposure prophylaxis and HIV postexposure
prophylaxis furnished without an individual prescription pursuant to the
requirements of section 2 of P.L.&nbsp;&nbsp;&nbsp;&nbsp;, c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the contract to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>A contract
offered by a </span>group or individual medical service corporation shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require a <span lang=EN>contract offered by a </span>group
or individual medical service corporation to provide coverage for HIV preexposure
prophylaxis or HIV postexposure prophylaxis furnished by a pharmacist at an
out-of-network pharmacy, unless the contract has an out-of-network pharmacy
benefit.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     d.</span>    <span
lang=EN>The provisions of this section shall apply to all contracts in which
the </span>group or individual medical service corporation<span lang=EN> has
reserved the right to change the premium.</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits coverage for the prophylaxis.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'>     5.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, n</span>o group
or individual health service corporation contract providing hospital or medical
expense benefits shall be delivered, issued, executed, or renewed in this State
or approved for issuance or renewal in this State by the Commissioner of
Banking and Insurance, on or after the effective date of this act, unless the
contract provides benefits to any subscriber or other person covered thereunder
for HIV preexposure prophylaxis and HIV postexposure prophylaxis furnished
without an individual prescription pursuant to the requirements of section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the contract to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>A contract
offered by a </span>group or individual health service corporation shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) (pending
before the Legislature as this bill) in excess of a 60-day supply for a single
patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require a <span lang=EN>contract offered by a </span>health
service corporation to provide coverage for HIV preexposure prophylaxis or HIV
postexposure prophylaxis furnished by a pharmacist at an out-of-network
pharmacy, unless the contract has an out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'>     <span lang=EN>d.    </span>The
provisions of this section shall apply to all contracts in which the health
service corporation has reserved the right to change the premium<span lang=EN>.</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits coverage for the prophylaxis.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, no </span>individual
health insurance policy providing hospital or medical expense benefits shall be
delivered, issued, executed, or renewed in this State or approved for issuance
or renewal in this State by the Commissioner of Banking and Insurance, on or
after the effective date of this act, unless the policy provides benefits to
any named insured or other person covered thereunder for HIV preexposure
prophylaxis and HIV postexposure prophylaxis furnished without an individual
prescription pursuant to the requirements of section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the policy to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>An </span>individual
health insurance policy shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1) prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require an individual health insurance policy to provide
coverage for HIV preexposure prophylaxis or HIV postexposure prophylaxis
furnished by a pharmacist at an out-of-network pharmacy, unless the contract
has an out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'>     <span lang=EN>d</span>.    The
provisions of this section shall apply to all policies in which the insurer has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits coverage for the prophylaxis.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, </span>no group
health insurance policy providing hospital or medical expense benefits shall be
delivered, issued, executed, or renewed in this State or approved for issuance
or renewal in this State by the Commissioner of Banking and Insurance, on or
after the effective date of this act, unless the policy provides benefits to
any named insured or other person covered thereunder for HIV preexposure
prophylaxis and HIV postexposure prophylaxis furnished without an individual
prescription pursuant to the requirements of section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the policy to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>A </span>group
health insurance policy shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require a group health insurance policy to provide
coverage for HIV preexposure prophylaxis or HIV postexposure prophylaxis furnished
by a pharmacist at an out-of-network pharmacy, unless the contract has an
out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'>     d.    The provisions of this
section shall apply to all policies in which the insurer has reserved the right
to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     <span lang=EN>e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, e</span>very
individual health benefits plan that is delivered, issued, executed, or renewed
in this State pursuant to P.L.1992, c.161 (C.17B:27A-2 et seq.) or approved for
issuance or renewal in this State, on or after the effective date of this act,
shall provide benefits to any person covered thereunder for expenses incurred <span
lang=EN>for</span> HIV preexposure prophylaxis and HIV postexposure prophylaxis
furnished without an individual prescription pursuant to the requirements of
section 2 of P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the plan to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>An </span>individual
health benefits plan shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;, c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require an individual health benefit plan to provide
coverage for HIV preexposure prophylaxis or HIV postexposure prophylaxis
furnished by a pharmacist at an out-of-network pharmacy, unless the contract
has an out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'>     d.    The provisions of this
section shall apply to all health benefit plans in which the carrier has
reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     9.    <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, </span>every
small employer health benefits plan that is delivered, issued, executed, or
renewed in this State pursuant to P.L.1992, c.162 (C.17B:27A-17 et seq.) or
approved for issuance or renewal in this State, on or after the effective date
of this act, shall provide benefits to any person covered thereunder for HIV
preexposure prophylaxis and HIV postexposure prophylaxis furnished without an
individual prescription pursuant to the requirements of section 2 of P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the plan to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    A small employer health
benefits plan shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require a small employer health benefit plan to provide
coverage for HIV preexposure prophylaxis or HIV postexposure prophylaxis
furnished by a pharmacist at an out-of-network pharmacy, unless the contract
has an out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'>     d.    The provisions of this
section shall apply to all health benefit plans in which the carrier has
reserved the right to change the premium. </p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     10.  <span lang=EN>a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, </span>notwithstanding
any provision of law to the contrary, a certificate of authority to establish
and operate a health maintenance organization in this State shall not be issued
or continued by the Commissioner of Banking and Insurance on or after the
effective date of this act unless the health maintenance organization provides
health care services to any enrollee for expenses incurred <span lang=EN>for</span> 
HIV preexposure prophylaxis and HIV postexposure prophylaxis furnished without
an individual prescription pursuant to the requirements of section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the plan to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <span lang=EN>A </span>health
maintenance organization shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require a health maintenance organization to provide
coverage for HIV preexposure prophylaxis or HIV postexposure prophylaxis
furnished by a pharmacist at an out-of-network pharmacy, unless the contract
has an out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'>     d.    The benefits shall be
provided to the same extent as for any other medical condition under the
contract.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits.</p>

<p class=MsoNormal style='line-height:150%'><sup><span style='font-family:"Albertus Extra Bold",sans-serif'>&nbsp;</span></sup></p>

<p class=MsoNormal style='line-height:150%'>     11.  a.  (1)  Notwithstanding
any State law or regulation to the contrary, and except as provided in
paragraph (2) of this subsection, the Department of Human Services shall ensure
that the provision of benefits for HIV preexposure prophylaxis and HIV
postexposure prophylaxis furnished without an individual prescription pursuant
to the requirements of section 2 of P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) to eligible persons under the
Medicaid program, established pursuant to P.L.1968, c.413 (C.30:4D-1 et seq.),
shall be provided without the imposition of any prior authorization or step
therapy requirements.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the department to ensure coverage
of all therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'>     b.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits coverage for the prophylaxis.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     12.  a.  (1)  </span>Except
as provided in paragraph (2) of this subsection<span lang=EN>, </span>the State
Health Benefits Commission shall provide benefits to each person covered under
the State Health Benefits Program for expenses incurred <span lang=EN>for </span>HIV
preexposure prophylaxis and HIV postexposure prophylaxis furnished without an
individual prescription pursuant to the requirements of section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) without requiring prior
authorization or step therapy.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If the federal Food and
Drug Administration has approved one or more therapeutic equivalents of a drug,
device, or product for the prevention of HIV and AIDS, paragraph (1) of this
subsection shall not be construed to require the contract to cover all
therapeutically equivalent versions without prior authorization or step
therapy, if at least one version is covered without prior authorization or step
therapy.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     b.    T</span>he
State Health Benefits Commission shall not:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   prohibit, or permit a
delegated pharmacy benefits manager to prohibit, a pharmacist from dispensing
HIV preexposure prophylaxis or HIV postexposure prophylaxis; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   be required to cover HIV
preexposure prophylaxis that has been furnished by a pharmacist without an
individual prescription pursuant to pursuant to section 2 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill) in excess of a 60-day supply for
a single patient within a given two year period.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Nothing in this section
shall be construed to require the State Health Benefits Commission to provide
coverage for HIV preexposure prophylaxis or HIV postexposure prophylaxis
furnished by a pharmacist at an out-of-network pharmacy, unless the contract
has an out-of-network pharmacy benefit.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     d.    </span>The
benefits shall be provided to the same extent as for any other medical
condition under the contract.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     e.     </span>As
used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     HIV preexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     HIV postexposure prophylaxis
means the same as that term is defined in section 1 of
P.L.&nbsp;&nbsp;&nbsp;&nbsp;,
c.&nbsp;&nbsp;&nbsp;&nbsp;(C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
(pending before the Legislature as this bill).</p>

<p class=MsoNormal style='line-height:150%'>     Step therapy means requiring
that a lower-cost alternative to HIV preexposure prophylaxis or HIV
postexposure prophylaxis be shown to have been ineffective as a condition of
providing prescription benefits.</p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'><span lang=EN>     </span>13.  The
Commissioner of Human Services shall apply for such State plan amendments or
waivers as may be necessary to implement the provisions of section 11 of this
act and to secure federal financial participation for State Medicaid
expenditures under the federal Medicaid program.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     14.  a.  Within 90 days after
the date of enactment of this act, and notwithstanding the provisions of the
Administrative Procedure Act, P.L.1968, c.410 (C.52:14B-1 et seq.) to the
contrary, the State Board of Pharmacy, in consultation with the Department of
Health, immediately upon filing proper notice with the Office of Administrative
Law, shall adopt rules and regulations as may be necessary to implement the
provisions of this act.</p>

<p class=MsoNormal style='line-height:150%'>     b.    The rules and
regulations adopted pursuant to subsection a. of this section shall be in
effect for a period not to exceed one year from the date of filing.  These
rules and regulations shall thereafter be adopted, amended, or readopted by the
board, in consultation with the Department of Health, in accordance with the
requirements of the Administrative Procedure Act, P.L.1968, c.410 (C.52:14B-1
et seq.).</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     15.  This act shall take
effect immediately.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill authorizes
pharmacists to dispense HIV prophylaxis without an individual prescription
under certain circumstances, and requires prescription benefits coverage for
prophylaxis furnished under the bill.</p>

<p class=MsoNormal style='line-height:150%'>     HIV prophylaxis is a course of
treatment involving certain drug combinations that can prevent HIV infection
notwithstanding exposure to the virus under circumstances in which it is
normally transmitted, such as through unprotected sexual contact, sharing
needles, or other contact with an infected persons blood or bodily fluids. 
HIV prophylaxis includes both HIV preexposure prophylaxis (PrEP), which is
taken by a person who anticipates engaging in conduct that risks HIV infection,
and HIV postexposure prophylaxis (PEP), which is taken by a person who may have
been exposed to HIV.</p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, pharmacists
will be permitted to furnish PrEP and PEP to patients without an individual
prescription pursuant to a standing order issued by the Commissioner of Health
or, if the commissioner is not a duly licensed physician, the Deputy
Commissioner for Public Health Services.  A standing order will be issued to a
pharmacist upon request, provided that the pharmacist completes a training
program approved by the State Board of Pharmacy in consultation with the
Department of Health, and certifies that the pharmacist will meet the requirements
set forth in the bill to furnish PrEP and PEP without an individual
prescription.  The training program is to include information about financial
assistance programs available to patients to assist with the costs of PrEP and
PEP.</p>

<p class=MsoNormal style='line-height:150%'>     The bill allows a patient to
receive up to a 60-day supply of PrEP without an individual prescription in any
given two-year period.  Thereafter, to continue receiving PrEP, the patient
will be required to obtain a prescription for the drugs.  A pharmacist
furnishing PrEP to a patient without an individual prescription will be
required to document that the patient is HIV negative, as demonstrated by a
test administered in the past seven days, and that the patient does not report
any signs or symptoms of acute HIV infection.  If the patient does not have a
current HIV test, the pharmacist may order a test.  If the patient tests
positive for HIV, the pharmacist will be required to provide the patient with
information and resources concerning HIV treatment and comply with State and
federal requirements for a positive HIV test, which includes certain reporting
requirements. </p>

<p class=MsoNormal style='line-height:150%'>     Additionally, the pharmacist
will be required to confirm that the patient is not taking any contraindicated
medications, provide the patient with counseling on the ongoing use of PrEP,
advise the patient that the patient will require a prescription to continue
receiving PrEP, confirm the patient has not already been provided with a 60-day
supply of PrEP without an individual prescription in the past two years,
document the services provided, and notify the patients primary care provider
that the patient was furnished with PrEP, unless the patient does not consent
to the pharmacist providing this notice.  </p>

<p class=MsoNormal style='line-height:150%'>     Pharmacists may furnish a
complete course of PEP to a patient who may have been exposed to HIV if the
pharmacist confirms with the patient that the exposure to HIV occurred within
the previous 72 hours, the patient otherwise meets the clinical criteria for
PEP consistent with guidelines published by the federal Centers for Disease
Control and Prevention (CDC), the pharmacist tests the patient for HIV, the
pharmacist counsels the patient on the use of PEP consistent with CDC
guidelines, the pharmacist informs the patient of the availability of PrEP, and
the pharmacist notifies the patients primary care provider the patient was
furnished with PEP, unless the patient does not consent to the pharmacist
providing this notice.  </p>

<p class=MsoNormal style='line-height:150%'>     If a patient being furnished
with PrEP or PEP does not have a primary care provider, or refuses to consent
to the pharmacist providing notice to the primary care provider, the pharmacist
will be required to provide the patient with a list of health care providers to
contact regarding ongoing treatment using PrEP or follow-up care for PEP, as
applicable.  The DOH will be required to publish and maintain a current list of
providers for pharmacists to use for this purpose, which list may be made
available on the departments Internet website.</p>

<p class=MsoNormal style='line-height:150%'>     In no case will a patient be
authorized to waive the consultation required under the bill to receive PrEP or
PEP without an individual prescription.</p>

<p class=MsoNormal style='line-height:150%'>     The bill requires health
benefits plans that include prescription benefits, as well as the State
Employees Health Benefits Plan, the School Employees Health Benefits Plan,
and Medicaid, to provide coverage for PrEP and PEP furnished under the bill
without any prior authorization or step therapy requirements.  If therapeutic
equivalents to prevent HIV and AIDS are approved, the health plans may apply
prior authorization or step therapy requirements to other versions of the
treatment, provided at least one version is covered without prior authorization
or step therapy.  Health plans will not be authorized to prohibit a pharmacist
from dispensing PrEP and PEP.  Health plans will not be required to provide
coverage for PrEP furnished without an individual prescription in a quantity
that exceeds a 60-day supply within a given two-year period.  Health plans will
not be required to cover PrEP or PEP furnished by a pharmacist at an
out-of-network pharmacy unless the plain includes an out-of-network pharmacy
benefit.</p>

</div>

</body>

</html>
